CA
REGN icon

Cynosure Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Cynosure Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-760
Closed -$286K – 239
2017
Q4 		$286K Buy
+760
New +$308K 0.07% 185

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cynosure Advisors's REGN Position: Q1 2018 in Review

Cynosure Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2018, closing a stake of 760 shares — an estimated $286K sold.

Cynosure Advisors first reported a position in REGN in Q4 2017 and held it in 1 quarter. The position peaked at $286K in Q4 2017. 619 funds tracked by Wall St. Rank hold REGN as of Q1 2018.

  • Cynosure Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Cynosure Advisors sold 760 Regeneron Pharmaceuticals shares in Q1 2018, an estimated $286K.
  • Cynosure Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Cynosure Advisors's Regeneron Pharmaceuticals position peaked at $286K in Q4 2017.
  • 619 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2018.

Based on Cynosure Advisors's 13F filing for Q1 2018, filed 21 Jun 2018.